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Cancer immunotherapy is transforming the way cancer is treated. Different from the other, 
more traditional cancer therapies that are targeting tumor cells, cancer immunotherapy 
engages with the immune system to enable a better recognition and therefore killing of tumor 
cells. Treatment with T cell bispecific antibodies (TCB) has the potential to improve the 
survival of late stage cancer patients. However, many tumors escape by resistance 
mechanisms that prevent immune surveillance, for instance upon expression of co-inhibitory 
ligands on the tumor cell surface. Blocking the interaction of these ligands with inhibitory T 
cell proteins, such as CTLA-4 or PD-1, showed promising anti-tumor activity. The activation 
of T cell co-stimulatory receptors serves as another approach to boost a patient’s immune 
response.  
 
ICOS, a member of the Ig-like receptor family, is one such T cell co- stimulatory receptor 
expressed on Treg, Tfh and Th17 at baseline, as well as on literally all T cell subsets upon 
activation. In the present study a systematic assessment of ICOS expression on different 
healthy and tumor-derived immune subsets, on resting and activated T cells, activated in 
presence of different stimuli was performed. It could be shown that ICOS is comparably 
upregulated upon stimulation by anti-CD3 – anti-CD28 or by TCB. Moreover, for the first 
time, the potential therapeutic application of targeting ICOS with an agonistic anti-ICOS 
antibody in combination with TCB treatment was investigated. Several formats of a human, 
targeted ICOS antibody were generated and demonstrated an increased T cell activation, 
cytokine secretion and central memory T cell differentiation upon ICOS co-stimulation in the 
context of in vitro TCB activation. Single cell transcriptome analysis supported these findings 
and moreover revealed that the underlying signalling pathways of TCB and ICOS 
co-stimulation seem to be very similar, hence ICOS co-stimulation increases the magnitude 
of TCB-mediated T cell activation. 
 
Further investigations into the possible combination of ICOS signalling with checkpoint 
inhibition is recommended to better address the flexibility and dynamics of the adaptive 






Die Immuntherapie gewinnt in der Krebsbehandlung zunehmend an Bedeutung. Bei dieser 
Art von Behandlung ist es das Ziel, das Immunsystem des Krebspatienten zu (re-) aktivieren 
und somit die Tumorzellen zu bekämpfen.  
 
Der Einsatz T-Zell bispezifischer Antikörper (TZB) hat Potenzial zur Behandlung 
fortgeschrittener Tumorerkrankungen. Allerdings entwickeln viele Tumore 
Resistenzmechanismen, die eine Erkennung durch das Immunsystem verhindern oder die 
Immunantwort durch die Sekretion inhibierender Botenstoffe und die Expression spezifischer 
Liganden supprimieren. Präklinische Daten weisen darauf hin, dass die Kombination mit 
Antikörpern, welche T-Zell inhibierende Rezeptoren blockieren, die Therapieeffizienz 
verbessern können. Ein weiterer therapeutischer Ansatz ist die Aktivierung stimulierender 
T-Zell-Rezeptoren, um die Immunantwort zu verstärken. Dazu zählt der induzierbare T-Zell-
Kostimulator (ICOS), der auf allen aktivierten T-Zellen exprimiert wird und nach Bindung an 
seinen Liganden die Proliferation und Reifung der T-Zelle induziert.  
 
In dieser Arbeit wurde die ICOS-Expression auf verschiedenen Immunzellen gesunder 
Donoren oder Tumorpatientenproben bestimmt. Es konnte gezeigt werden, dass ICOS auf 
Tumor infiltrierenden T-Zellen hochreguliert und gemeinsam mit CTLA-4 und PD-1 
exprimiert wird. Desweiteren ist ICOS nach T-Zell Aktivierung durch anti-CD3 -anti-CD28 
Antikörper oder TZB gleichermassen exprimiert. Um den therapeutischen Nutzen des ICOS 
Signalweges im TZB Kontext besser verstehen zu können, wurden verschiedene, neuartige 
ICOS Antikörper im monovalenten und bivalenten Format generiert und in Kombination mit 
TZB auf ihre immunstimulierende Aktivität getestet. Die in vitro Kombination von TZB und 
ICOS Kostimulierung durch neuartige, humane ICOS Antikörper resultierte in erhöhter 
T-Zell Aktivierung, gesteigerter Zytokinsekretion und T-Zell Differenzierung. Gensignaturen 
auf Einzelzellebene deuteten darauf hin, dass besonders Gedächtnis-T-Zellen nach 
Stimulierung durch ICOS-Antikörper aktiviert werden, die durch TZB und ICOS 
Kostimulierung aktivierten Signalwege prinzipiell vermutlich aber ähnlich sein müssen.  
 
Der nächste Schritt wäre die Evaluierung der Kombination im Mausmodell. Neueste 




Kombination des ICOS-Signalweges mit T-Zell-Inhibitoren hin, um noch besser die 






3.1 Cancer immunotherapy 
 
Cancer is the second leading cause of death globally and every year more cases are diagnosed 
(World Health Organization, 2018). For many years, cancer treatment was tumor-centric, 
focusing on approaches such as surgery, radiotherapy, chemotherapy and targeted therapy 
(Chabner et al., 2005, Kobold et al., 2015). However, during the last decades the immune 
system has emerged as a promising, novel therapeutic target for cancer treatment (Hanahan et 
al., 2011, Kobold et al., 2015, Leach et al., 1996).  
 
Our immune system`s main function is the continuous recognition and control of foreign 
agents. These can be pathogens such as bacteria or viruses, but also cancer cells that arise 
from tumor-specific mutations distinguishing a malignant cell from the body`s own healthy 
tissues. The fact that cancerous cells can be recognized and eliminated by the host’s immune 
system is termed immune surveillance. The first proof of the immune system`s role in 
fighting cancer was presented in 1890 by William Coley. He observed that patients suffering 
from bacterial infections, having a pre-activated immune system, were superior in rejecting 
tumor cells (Ai et al., 2015). Moreover, a higher tumor burden can be observed in individuals 
whose immune system is suppressed (Delves et al., 2012). Various mechanisms are known 
that allow the tumor to evade the immune system`s control. This so called immune escape 
can occur as a consequence of several factors: (i) deficient tumor antigen recognition by 
effector immune cells due to down-modulation of tumor antigen; poor priming and activation 
of T cells in the secondary lymphoid organs due to up-regulation of immune checkpoint 
receptor ligands; (ii) deficient trafficking or infiltration of T cells into the tumor; recruitment 
of suppressive tumor-associated cells (as regulatory T cells (Treg cells), myeloid suppressor 
cells or tumor-associated macrophages); and (iii) the secretion of soluble factors such as 
cytokines and chemokines (Beatty et al., 2015, Dunn et al., 2004, Ventola, 2017a).  
 
Consequently, the main goal of cancer immunotherapy is to revive the suppressed immune 
system to eliminate cancer cells. This can be achieved by various approaches reaching from 
activation of adaptive and innate immune system components to neutralizing suppressive 




Strategies to enhance the patient’s immune response to fight cancer comprise the 
administration of cytokines, chemokines or growth factors that regulate immunity and 
inflammation. This non-specific approach can be interferon alpha (IFN-) or interleukin-2 
(IL-2) (Berraondo et al., 2018, Fisher et al., 2000). Cellular approaches include cancer 
vaccines displaying cancer antigens and thereby stimulating the immune system`s attack to 
recognize cancer (van Dodewaard-de Jong et al., 2016); cell-based therapies such as 
allogenic human stem cell transfer and adoptive T cell transfer. Neutralization of suppressive 
immune mechanism include the use of monoclonal antibodies that bind a tumor antigen and 
directly kill the tumor cell via mechanisms as antibody derived cellular cytotoxicity (e.g. 
rituximab (Maloney, 2001) or by being conjugated to toxic particles (Beck et al., 2017, 
Suzuki et al., 2016, Ventola, 2017a). During the last decade special attention was given to 
checkpoint inhibitors. Immunoinhibitory T cell receptors, referred to as immune checkpoint 
receptors, such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed 
cell death protein 1 (PD-1) guard from unwanted, self-directed immune responses by 
downregulation of T cell activation. Tumor cells make use of this mechanism by the 
up-regulation of immune checkpoint receptor ligands. This can turn the patient`s immune 
system off and promote tumor progression (Korman et al., 2006, Mahoney et al., 2015). 
Antibodies binding CTLA-4 or PD-1 and thereby blocking the inhibitory axis between tumor 
and T cells resulted in durable responses in patients with advanced cancer (Brahmer et al., 
2012, Schadendorf et al., 2015). Checkpoint inhibitors targeting CTLA-4 and PD-1 have 
been designated as important breakthroughs in the evolution of cancer immunotherapy 
(Couzin-Frankel, 2013) and honoured with the Nobel prize in physiology or medicine 2018.  
 
3.2 Relevance of T cells for cancer therapy  
 
For long-term protection against pathogens, adaptive immunity mediated by B and T 
lymphocytes is needed. The adaptive immune response is based on re-arrangement of B and 
T cell receptors to allow specific recognition of surface protein structures, so called antigenic 
epitopes. Maturation of T cells occurs in the thymus by positive and negative selection. As a 
result, naïve T cells arise, carrying T cell receptors (TCR) that allows specific recognition of 
ingested antigens presented in the grooves of the major histocompatibility complex (MHC) 
on antigen-presenting myeloid cells. T cells can be classified into CD8+ cytotoxic T cells 




distinguished based on their cytokine secretion pattern: Th1 cells (IFN-γ, IL-2), Th2 cells 
(IL-4, IL-5, IL-10), Th9 cells (IL-9, IL-10) or Th17 cells (IL-17A, IL-17F, IL-21, IL-22) 
(Dong et al., 2015, Geginat et al., 2014). 
 
Naïve T cells circulate through the body until they recognize MHC-presented peptide on 
antigen presenting cells (Fujimi et al.) matching their TCR. Following this initial T cell 
activation, a network of co-stimulatory as well as co-inhibitory receptors regulate the T cell 
response (Figure 1).  
 
 
Figure 1: Schematic overview of T cell co-stimulatory and co-inhibitory receptors  Upon T cell receptor 
(TCR) engagement with major histocompatibility complex (MHC) presented peptides on antigen-presenting 
cells (APC) a network of immunomodulatory, secondary receptors further regulating T cell activation and 
tolerance. Co-stimulatory (blue) as well as co-inhibitory (orange) receptors expressed on T cells and their 
corresponding ligand on APC are indicated. The shape indicates members of the tumor necrosis factor receptor 
superfamily (TNFRSF) or the immunoglobulin superfamily (IgSF). Figure has been adapted from an illustration 
published by (Mahoney et al., 2015). 
 
To ensure safe stimulation of the adaptive immune system, T cell activation requires a 
secondary, co-stimulatory signal. Co-signalling molecules can be subdivided into the tumor 
necrosis factor receptor (TNFR) or the the immunoglobulin (IgG)-like superfamily. 
Numerous members of the TNFR superfamily such as 4-1BB, Ox40, glucocorticoid-induced 
TNFR-related protein (GITR) and CD27 deliver stimulatory signals. However, the most 




Binding of the IgG-like superfamily member CD28 to its ligand CD80 or CD86 expressed on 
APC augments survival and proliferation of T cells. In order to control CD28-mediated T cell 
expansion, its inhibitory counter receptor CTLA-4 competes with CD28 for binding to CD80 
and CD86 and thereby prevents overstimulation of the immune system (Esensten et al., 2016, 
Rudd et al., 2009). Besides CTLA-4, engagement of the co-inhibitory receptor PD-1 with its 
ligand PD-L1 or PD-L2 expressed on APC or tumor cells can also transduce a signal that 
inhibits T cell activation and proliferation. In addition to the prototypic, co-stimulatory role 
of CD28 for T cell activation, the inducible T cell co-stimulator (ICOS) is another 
co-stimulatory receptor belonging to the immunoglobulin (IgG)-like superfamily. Given the 
important role of IgG-like superfamily members as targets for cancer immunotherapy, ICOS 
serves as an interesting, novel target for modulation of immune response by T cell 
co-stimulation (Mahoney et al., 2015).  
 
3.3 Inducible T cell co-stimulator (ICOS) 
 
ICOS is a co-stimulatory cell surface receptor that is upregulated upon TCR engagement. 
Belonging to the IgG-like superfamily, ICOS is structurally related to CD28 and CTLA-4. 
ICOS is expressed as a disulfide-linked homodimer consisting of two single extracellular 
immunoglobulin variable-like (IgV) domains coupled to a transmembrane domain and a 
cytoplasmic tail (Hutloff et al., 1999). The expression of ICOS is described to be restricted to 
T cells (Ogasawara et al., 2002). Low levels of ICOS can be found on resting naïve Th1 and 
Th2 effector T cell populations (Paulos et al., 2010) while higher levels are expressed on 
resting Th17, follicular helper T cells (Tfh) and Treg cells. However, unlike CD28, which is 
constitutively expressed on naïve T cells, ICOS is strongly upregulated on all T cell subsets 
by stimulation of the TCR complex (Hutloff et al., 1999, Yoshinaga et al., 1999). 
 
ICOS binds exclusively to its ligand, the so-called ICOS ligand (ICOSL, B7H2, B7RP-1), 
which is expressed on B cells, macrophages, dendritic cells (DC), and non-immune cells 
treated with TNF-α (Simpson et al., 2010, Swallow et al., 1999). Even though structurally 
related, ICOS cannot bind, nor is it activated by, the ligands for CD28 and CTLA-4. This can 
be explained by the lack of amino acid MYPPY motif in ICOS which is necessary for CD28 
and CTLA-4 to bind their ligands CD80 (B7-1) and CD86 (B7-2). However, ICOSL has been 





Ligation of ICOS with ICOSL induces intracellular signalling through the 
phosphatidylinositol-3 kinase (PI3K) and AKT pathways (Hutloff et al., 1999). PI3K-AKT 
signalling regulates numerous processes, including cell growth, differentiation, survival, 
proliferation, migration and cell metabolism (Slomovitz et al., 2012). The cytoplasmic tail of 
ICOS carries a unique YMFM SH2 motif. Following ICOSL binding the p50α and p85α 
regulatory adaptor subunits are recruited to this YMFM SH2 motif. The preferred recruitment 
of p50α results in greater PI3K lipid kinase activity and phosphorylation of AKT (Fos et al., 
2008). In contrast, the p85α directly binds and translocates osteopontin (OPNi) to the nucleus 
resulting in preservation the Tfh lineage defining factor Bcl6. Another ICOS specific 
signalling pathway is the activation of the NFkB member TANK-binding kinase 1 (TBK1) 
that gets recruited by the ICOS proximal (IProx) motif. TBK1 was shown to directly control 
maturation, function and phenotype maintenance of germinal center Tfh cell and B cell 
responses (Pedros et al., 2016, Wikenheiser et al., 2016). The ICOS-ICOSL pathway also 
plays a central role in Th1 as well as Th2 responses (Greenwald et al., 2002, Maazi et al., 
2015) during autoimmunity, bacterial infections (Marriott et al., 2015), graft rejection (Sato 
et al., 2013) and recently a growing body of literature is highlighting the role of ICOS 
signalling in tumor cell rejection (Hubbard et al., 2005, Metzger et al., 2016, Mo et al., 2017, 
Odegard et al., 2008, Zamarin et al., 2017).  
 
Two classes of therapeutic ICOS antibodies are currently being tested in clinical or pre-
clinical approaches. These can be differentiated by their mode of action (see Figure 2). The 
first class of antibodies (Figure 2, A) induces Fc-mediated lysis of ICOS+- T cells 
(preferentially Treg cells). Simultaneous binding to ICOS and binding of the antibody’s 
wild-type Fc part to Fc receptors (FcR) expressed on NK cells or macrophages, leads to 
antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular 
phagocytosis (ADCP). Lytic proteins, such as perforins or granzymes being released by NK 
cells or macrophages result in lysis of the ICOS+- T cells. The second class of ICOS 
antibodies (Figure 2, B) induces ICOS agonism upon crosslinking of ICOS+- T cells by 
binding to an ICOS antigen binding domain and a target antigen binding domain. The 
introduction of a genetically modified, inert Fc avoids Fc-mediated ADCC or ADCP (Delves 






Figure 2: Schematic overview of two classes of therapeutic ICOS antibodies (A) ICOS antibodies mediating 
lysis of ICOS+- T cell via antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular 
phagocytosis (ADCP). Crosslinking of ICOS antibodies upon binding to ICOS+ on T cell and Fc receptor (FcR) 
on NK cell or macrophages results in lysis of ICOS+- T cell mediated by the release of lytic proteins (perforine 
and granzymes). (B) ICOS antibodies mediating ICOS agonism. Crosslinking of ICOS antibodies upon binding 
to ICOS+- T cell and target cell induced ICOS agonism of the ICOS+ T cell. No FcR-mediated effects due to 
inert Fc part. Figure has been generated based on information published by (Sainson et al., 2018, Sazinsky, 
2016). 
 
3.4 T cell bispecific antibody therapy  
 
T cell bispecific (TCB) molecules are a specific class of antibodies engineered to activate T 
cells upon simultaneous binding of a tumor surface antigen and the CD3ɛ subunit of the TCR 
complex. Simultaneous engagement of a tumor-associated antigen and CD3 results in 
MHC-independent recruitment of T cells to the tumor site; moreover, T cells become 
activated and ultimately induce tumor cell lysis by the secretion of cytotoxic granules and 
other cytokines (Dahlen et al., 2018, Delves et al., 2012, page 253, Martinez-Lostao et al., 
2015). Two main types of TCB can be differentiated: 1) Fc-free bispecific molecules as the 
CD19-CD3 targeting Blinatumomab (Sanford, 2015); 2) Fc-bearing IgG-like TCB, showing 
prolonged in vivo pharmacokinetics. One example of a Fc-carrying TCB is CEA-TCB, whose 
mode of action is affected via bivalent binding to human CEA and monovalent binding to 
CD3ɛ and is currently in clinical trials in late stage metastatic colorectal cancer (Bacac, Fauti, 
et al., 2016, Bacac, 2016). Pre-clinical and first clinical studies using CEA-TCB showed a 
























tumor cells. Furthermore, CEA-TCB resulted in the upregulation of the suppressive receptor 
PD-1 on T cells. Currently CEA-TCB is tested in combination with the checkpoint inhibitor 
anti-PD-L1 antibody atezolizumab to block suppressive signalling through PD-1/PD-L1 and 
thereby achieve maximal T cell mediated anti-tumor responses (Bacac, Fauti, et al., 2016). 
 
3.5 Combination therapies  
 
The development of cancer immunotherapeutic agents relies on the continuous understanding 
the biology of cancer and immune cells. Successfully harnessing the immune system to treat 
cancer requires approaches that address the dynamics and flexibility of the immune system. 
Examples of constant immune adaption, as reported for example in the TCB-mediated 
upregulation of PD-1, made us understand that combination approaches are essential to 
achieve long-term or complete tumor remission. A growing body of combinations is currently 
being tested clinically or pre-clinically, including the concomitant administration of immune 
checkpoint inhibitors with surgery, radiation or chemotherapy (Mayes et al., 2018, Pardoll, 
2012). Very promising results could be observed when combining immune checkpoint 
inhibitors ipilimumab (anti-CTLA-4) with nivolumab (anti-PD-1), resulting in an objective 
response rate of 50-60 % in advanced-stage melanoma patients (Postow et al., 2015).  
 
In the course of anti-CTLA-4 clinical studies in bladder cancer and melanoma, ICOS is 
upregulated on effector T cells and serves as a biomarker for ipilimumab therapy efficacy in 
melanoma patients. Moreover, follow-up studies in mice revealed that agonizing the ICOS 
pathway by overexpression of ICOSL on tumor cells could further improve anti-CTLA-4 
mediated anti-tumor response (Fan et al., 2014, Fu et al., 2011, Ng Tang et al., 2013). 
Administration of ICOS signal alongside with anti-Ox40 therapy led to enhanced tumor 
rejection and survival (Metzger et al., 2016). In summary, this supports the idea of ICOS 








Various pre-clinical studies show the relevance of agonizing T cell co-stimulatory receptors 
to improve current cancer immunotherapy approaches (Mahoney et al., 2015, Mayes et al., 
2018). It has been found that combining CEA-TCB with the checkpoint inhibitor PD-L1 
results in improved anti-tumor efficacy (Bacac, Fauti, et al., 2016). Similarly, promising 
results have recently been reported on the combination of CEA-TCB with TNFR-superfamily 
member 4-1BBL (Sam, 2018). However, the combination with co-stimulatory IgG-like 
superfamily members has not been investigated yet.  
 
The aims of this thesis are: 
1. Gain a better understanding of: 
a. ICOS expression on healthy but also tumor-derived human T cells 
b. Kinetics of ICOS expression compared to other immunomodulatory receptors on 
human T cells  
c. ICOS expression at baseline and upon TCR or CD3 stimulation on effector and 
regulatory T cells  
2. Generate and validate novel agonistic anti-ICOS antibodies 
3. Test the hypothesis that agonizing ICOS signalling can further boost TCB-mediated 
anti-tumor therapy  
 
Providing the first signal to T cells via TCB induces the expression of ICOS (Figure 3, step 
1). Subsequent ICOS co-stimulation, using an agonistic ICOS antibody, is anticipated to 
enhance and prolong T cell immunity (Figure 3, step 2) resulting in an improved and 






Figure 3: Hypothesis of ICOS signalling in the context of TCB-mediated anti-tumor therapy. TCB 
simultaneously binding a tumor surface antigen and the CD3ɛ subunit of the TCR complex provides the primary 
T cell signal (signal 1) and thereby induces the expression of ICOS (1). Co-stimulation with an agonistic ICOS 
antibody is anticipated to enhance T cell activation (2), finally expected to result in an improved and 
long-lasting anti-tumor response (3). Figure has been generated based on information published by (Corraliza-







4.1 Plastic ware  
 
 96-well flat-bottom or round-bottom cell culture plate, TPP, Switzerland 
 Cell culture flask T25, T75, T150, TPP, Switzerland 
 Cell strainer 70 m, 40 m,Fisher Scientific, Switzerland 
 Eppendorf Safe-Lock Tube 1.5 ml, Eppendorf, Switzerland 
 Eppendorf DNA LoBind Tube 1.5 ml, Eppendorf, Switzerland 
 Falcon tubes 50 ml, 15 ml, TPP, Switzerland 
 LS, MS, LD columns, Miltenyi Biotec GmbH, Switzerland 
 NuPAGE® Novex® 3 – 8 % Tris-Acetate Protein Gels, Fisher Scientific, Switzerland  
 NuPAGE® Novex® 4 – 12 % Bis-Tris Protein Gels, Fisher Scientific, Switzerland 
 SepMate50 Tubes, StemCell Technologies, Germany 
 Syringe 3 ml, 5 ml, BD, SWITZERLAND Bioscience 
 




 Chromium Single Cell 3`Reagent Kit, 10x Genomics 
 Cytotoxicity Detection Kit (LDH), Roche, Switzerland 
 FoxP3 intracellular staining kit, BioLegend, Switzerland 
 LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit, Thermo Scientific, Germany 
 NucleoSpin® Gel and PCR Clean-up, MACHEREY-NAGEL, Switzerland  
 NucleoSpin® Plasmid, MACHEREY-NAGEL, Switzerland 
 Taq PCR core kit, Qiagen, Switzerland 




 1 x PBS (Phosphate-buffered saline), Gibco, UK 




 Antibiotic-antimycotic 100 x (anti-anti), Fisher Scientific, Switzerland 
 BSA, Sigma-Aldrich AG, Switzerland 
 CD CHO, Fisher Scientific, Switzerland 
 Cell Dissociation Buffer, Fisher Scientific, Switzerland 
 Cell Trace CFSE Dye, Fisher Scientific, Switzerland 
 Collagenase D, Roche, Mannheim Germany 
 D - (+) - Glucose, Sigma-Aldrich AG, Switzerland 
 Dimethyl sulfoxide (DMSO), Sigma-Aldrich AG, Switzerland  
 DNAse, Sigma-Aldrich AG, Switzerland 
 Dulbecco's Modified Eagle Medium (DMEM), Fisher Scientific, Switzerland 
 Ex-Cell 293 Serum-Free Medium for HEK 293 Cells, Sigma-Aldrich AG, Switzerland 
 Fetal calf serum (FCS), Gibco, UK 
 G418, Geneticin®, Sigma-Aldrich AG, Switzerland 
 GlutaMaxTM, Fisher Scientific, Switzerland 
 Golgi Plug, BD, Switzerland 
 Golgi Stop, BD, Switzerland 
 Histopaque, Sigma-Aldrich AG, Switzerland 
 Hyaluronidase, Sigma-Aldrich AG, Switzerland 
 Hygromycin B, Sigma-Aldrich AG, Switzerland 
 MACS Tissue Storage Solution, Miltenyi Biotec, GmbH, Switzerland 
 Non-essential amino acids, Sigma-Aldrich AG, Switzerland 
 Paraformaldehyde (10 % Formalin), Sigma-Aldrich AG, Switzerland 
 Permeabilization buffer, BioLegend, Switzerland,  
 Proleukine, FarmaMondo, USA 
 Puromycin (c = 10 mg/ml), InvivoGen, LabForce AG, Switzerland 
 RPMI1640, Fisher Scientific, Switzerland 
 Sodium bicarbonate NaHCO3, Sigma-Aldrich AG, Switzerland 
 Sodium pyruvate, Sigma-Aldrich AG, Switzerland 
 Triton X-100, BioRad AG, Switzerland 
 Trypsin - EDTA, 0.05 %, Fisher Scientific, Switzerland 
 Tween20, Roche, Switzerland 




 Valproic acid, Sigma, Schweiz 




 Anti-human CD197 (CCR7), G043H7, BioLegend, Switzerland 
 Anti-human CD25, BC96, BioLegend, Switzerland 
 Anti-human CD3, HIT3a, BioLegend, Switzerland 
 Anti-human CD4, RPA-T4, BioLegend, Switzerland 
 Anti-human CD45, HI30, BioLegend, Switzerland 
 Anti-human CD45 (RO), UCHL-1, BioLegend, Switzerland 
 Anti-human CD69, FN50, BioLegend, Switzerland 
 Anti-human CD8, SK1, BioLegend, Switzerland 
 Anti-human CTLA-4, L3D10, BioLegend, Switzerland 
 Anti-human Fc (Fab)2 PE conjugated, R&D Systems, Bio-Techne AG, Switzerland  
 Anti-human FoxP3, 206D, BioLegend, Switzerland 
 Anti-human ICOS, C398.4A, BioLegend, Switzerland 
 Anti-human PD-1, EH12.2H7x, BioLegend, Switzerland 
 LEAF anti-human CD28, CD28.2, BioLegend, Switzerland 
 LEAF anti-human CD3, OKT3, BioLegend, Switzerland 
 
4.1 Buffers and media 
 
Table 1: Buffers and media 
BUFFER SOURCE  
FACS Buffer 1 x PBS, 2 % FCS, 5 mM EDTA, 0.25 % sodium azide  
Fixation Buffer 1 x PBS, 4 % PFA  
MEDIA SOURCE  
Human T cell media RPMI1640, 10 % FCS, 1 % GlutaMaxTM, 1 µM sodium 






4.2 Cell lines 
 
Table 2: Cell lines 
CELL LINE  SOURCE  PROVIDER MEDIA 
3T3-hFAP Mouse fibroblast, parental 3T3, transfected to 
stably overexpress human FAP 
ATCC, CCL-
92 
DMEM, 10 % FCS, 1 % 
GlutaMaxTM, 1.5 µg/ml 
Puromycin 
CHO-hICOS Parental CHO-K1, Chinese hamster ovary cell 
line transfected to stably overexpress human 
ICOS 
ATCC, CCL-61 DMEM, 10 % FCS, 1 % 
GlutaMaxTM, 6 µg/ml 
Puromycin 
HEK293EBNA Human embryonic kidney cell line ATCC, CRL-
1573 
Ex-Cell293, 6 mM, 1 % 
GlutaMaxTM, 6 µg/ml 
G418 
MKN45 Human gastric adenocarcinoma cell line DSMZ ACC409 RPMI1640, 10 % FCS, 
1 % GlutaMaxTM 
MV3 Human melanoma metastatic cell line CVCL_W280 DMEM, 10 % FCS, 1 % 
GlutaMaxTM 
 
4.3 Tumor samples  
 
Human tumor samples were received from University Hospital Zurich (Switzerland) based on 
ethical approval between USZ and Roche granted by the Kantonale Ethikkommission Zürich. 
The day of surgery or the day after tumor samples were shipped on ice. Tumor samples were 
stored in MACS Tissue Storage Solution until used for further processing.  
 
4.4 Technical equipment 
 
 Aekta Purifier, GE Healthcare, Switzerland, Protein purification 
 Steri-Cycle i160, Thermo Scientific, Germany, CO2 incubator 
 Safe 2020, Thermo Scientific, Germany, Sterile safety hood  
 Centrifuge 5810 R, Eppendorf, Switzerland, Centrifugation 
 Centrifuge 5424 R, Eppendorf, Switzerland, Centrifugation  
 Olympus CKX53, Olympus, Switzerland, Microscope  
 Cedex HiRes, Roche, Switzerland, Cell counter 




 Rocker 3D digital, IKA, Germany, Shaking table 
 Quadro MACS, Miltenyi Biotec, GmbH, Switzerland, Magnetic separator 
 Tecan Spark 10M, Tecan, Switzerland, Plate reader 
 MixMate, Eppendorf, Germany, Samples mixing  
 Platemaster, Gilson AG, Switzerland, Semi-automated pipetting of 96-well plates 
 Dropsense BioPhotometer, Trinean, Switzerland, Protein/DNA concentration 
 Mastercycler proS, Eppendorf, Switzerland, PCR 
 Caliper LabChip GXII System, Perkin Elmer, USA, Capillary electrophoresis 
 Biacore T200, GE Healthcare, Switzerland, SPR analysis 
 FACS AriaIII, BD Bioscience, Switzerland, Flow cytometry, Cell Sorting  
 FACS Fortessa LSR, BD Bioscience, Switzerland, Flow cytometry 




 GraphPad Prism 6.07, Graphical and statistical analysis 
 CloneManager 9, Planing of molecular cloning 
 FACS Diva, FACS data analysis 
 FlowJo V10, FACS data analysis 
 Tibco Spotfire, Graphical and statistical analysis 
 Biacore T200 Evaluation Software (version 3.1), SPR (analysis protein purification) 




5 Methods  
 
5.1 Generation of antibodies 
 
5.1.1 Molecular cloning  
 
The target gene sequence was cloned into a light chain or a heavy chain containing plasmids 
vectors (pSTAN1 and derivates; origin by Roche Innovation Center Zurich). Therefore, 
plasmids were enzymatically digested, followed by ligation with T4 ligase. Amplification of 
the plasmid was done by heat-shock transformation of XL-1 chemo competent bacteria with 
the ligated DNA and cultivated on an agarose plate containing the proper antibiotic for 
selection of positively transformed bacteria. Plasmid DNA was purified from bacteria 




Expression of human antibodies was achieved by transient co-transfection of HEK293 EBNA 
suspension cells with plasmid DNA using polyethylenimine (PEI, Polysciences Inc.). 
Therefore 2 x 107 cells resuspended in 20 ml CD CHO media were mixed with 10 g plasmid 
DNA (1 g/ml) and 27 l PEI (1 mg/ml). After 3 h incubation at 37 °C, 5 % CO2, 135 rpm 
another 80 ml of ExCell media (6 mM L-glutamine, 5 g/l Ultrapep Soy, 1.2 mM valproic 
acid) was added and further incubated. 24 h post transfection, cells were supplied with feed 
and 3 g/l glucose. After six days incubation, antibodies secreted to the cell supernatant were 
harvested by centrifugation (210 x g, 30 min) and sterile filtered (0.22 μm filter „rapid“, 
TPP). Supernatant was stored at 4 °C for subsequent protein purification.  
 
5.1.3 Protein purification  
 
Secreted proteins were purified from cell culture supernatants by affinity chromatography 
using Protein A followed by size exclusion chromatography (SEC). For affinity 
chromatography, the sterile filtered supernatant was loaded on a Protein A MabSelectSure 
column (CV = 5 mL, GE Healthcare) equilibrated with 40 ml of 20 mM sodium phosphate, 




column volumes of 20 mM sodium phosphate, 20 mM sodium citrate, pH 7.5. The bound 
protein was eluted using a linear pH-gradient of sodium chloride (from 20 mM to 100 mM) 
created across 15 column volumes of 20 mM sodium citrate, 100 mM sodium chloride, 
100 mM Glycine, 0.01 % Tween20 pH 3.0. The column was then washed with 10 column 
volumes of 20 mM sodium citrate, 100 mM NaCl, 100 mM Glycine, 0.01 % Tween20, 
pH 3.0. The pH of collected fractions was adjusted by directly adding 2 M Tris, pH 8.0. The 
protein was concentrated and filtered using Amicon®Ultra-15 Ultracel 30 K columns prior to 
loading on a HiLoad Superdex 50/600 S200 column (GE Healthcare) equilibrated with 
20 mM Histidine, 140 mM NaCl, 0.01 % Tween20, pH 6.0. 
 
5.1.4 Quality control  
 
The concentration of purified proteins was determined by measuring the optical density (OD) 
at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid 
sequence using the Dropsense biophotometer.  




Quality control of the antibodies was performed by the Process Biochemistry group of Roche 
Innovation Center Zurich. This comprised the purity, molecular weight and aggregate content 
of the antibodies using capillary electrophoresis (LabChipGXII (Caliper) and analytical size-
exclusion column (TSKgel G3000 SW XL, Tosoh). Also the heat stability (heated up from 
25 °C to 85 °C using a heating rate of 0.1 °C/min) of the antibodies was tested using an 
Optim2 device.  
 
5.2 Cell culture techniques 
 
5.2.1 Cultivation of tumor cell lines 
 
All cell lines were cultured at 37 °C in a water-saturated atmosphere at 5 % CO2 
(Steri-CycleTM i160). All manipulations were performed with sterile reagents under a laminar 
flow hood. Adherent cells were dissociated using 0.05 % Trypsin – EDTA or Cell Dissociation 




Cell number and viability was determined by trypan blue staining using the Cedex HiRes cell 
counter. 
 
5.2.2 Human PBMC isolation 
 
Human peripheral blood mononuclear cells (PBMC) were isolated either from fresh blood or 
buffy coat (from irreversibly anonymized donors obtained from Blutspendezentrum Zürich) 
by standard Histopaque density gradient centrifugation using SepMate tubes. In brief, human 
blood or buffy coat was mixed with equal volume of 1 x PBS and gently added to the 
SepMate tubes by pipetting down at the wall of the tube. After 10 min centrifugation at 
1200 x g the supernatant was poured into a fresh tube, followed by several washing steps. 
Wash the cells by filling up the tube with 1 x PBS, centrifuge (400 x g, 10 min), aspirate 
the supernatant and resuspended the pellet. Repeat the washing step by resuspending the 
pellet with 1 x PBS and centrifuge (300 x g, 10 min), followed by a final washing step 
resuspending the pellet with 1 x PBS and centrifuge (350 x g, 10 min). In order to remove 
remaining red blood cells, a lysis step using ACK Lysis buffer was performed. Therefore, 
5 ml of ACK Lysis Buffer were added. After 5 min incubation at 37 °C cells were washed 
with 1 x PBS and centrifuged (350 x g, 10 min).  
 
5.2.3 Tumor tissue digest  
 
Human tumors were minced into very small pieces using two sterile scalpels. Pieces were 
transferred into a fresh 50 ml Falcon tube, 10 ml of enzymatic digestion mix (RPMI1640, 
2 % FCS, 10 U/ml DNaseI, 275 U/ml collagenase D, 471 U/ml Hyaluronidase) was added 
and incubated for 30 min at 37 °C on a rotator with medium speed. Thereafter the tumor 
pieces were filtered through a 70 μm mesh using the plunger of a 10 ml syringe and washed 
three times with cold 1 x PBS. Samples were centrifuged for 10 min at 250 x g and 4 °C, 
followed by resuspension of the pellet in the required buffer.  
 
5.3 Flow cytometry  
 
For this thesis, all data were acquired on a FACS Fortessa instrument, equipped with Diva 




yellow/green (561 nm), red (633 nm)). The lasers with their adequate filter bands allow the 
simultaneous multi-parameter analysis and thereby the characterization of single cells and 
their antigens.  
If not otherwise stated, all steps were carried out at 4 °C to prevent internalization of the 
antibodies. 96-well plates were centrifuged for 5 min at 350 x g, FACS tubes for 4 min at 
400 x g. Plate-coating of antibodies was performed by diluting the antibody in 1 x PBS 
followed by either overnight incubation at 4 °C or 3 h incubation at 37 °C.  
 
5.3.1.1 Surface staining 
 
For the discrimination of live and dead cells, cells were labelled with the fixable Zombie UV 
viability dye. After washing with 1 x PBS, cells were incubated for 30 min at 4 °C with 50 µl 
of the antibody diluted at the appropriate concentration in FACS buffer, washed three times 
by adding 200 µl of FACS buffer, followed by centrifugation. If immediately acquired, cells 
were resuspended in 200 µl of FACS buffer. Otherwise, the cells were fixed by resuspending 
the pellet in 100 µl of 4 % PFA and incubating for 15 min at room temperature. After three 
times washing, cells were stored in FACS buffer until acquisition by flow cytometry (5.3). 
 
5.3.1.2 Intracellular staining 
 
For intracellular staining cells were resuspended in 1 x Perm/Fix buffer (FoxP3 intracellular 
staining kit, BioLegend) for 45 min at room temperature. After three times washing with 
1 x Perm buffer, cells were incubated for 40 min at room temperature in 1 x Perm buffer 
containing the antibody for intracellular staining. Cells were washed three times using 
1 x Perm buffer, followed by resuspension of the pellet in the required volume of FACS 
buffer for acquisition by flow cytometry (5.3). 
 
5.4 Binding of antibody constructs to cells 
 
Cells were harvested, counted, checked for viability and re-suspended at 106 cells per ml in 
FACS buffer. 100 µl of the cell suspension (containing 105 cells) were incubated in 96-well 
round-bottom plates for 30 min at 4 °C with increasing concentrations (7 pM – 120 nM) of 




further 30 min at 4 °C with a fluorochrome-conjugated, secondary antibody and washed 
again. If not acquired immediately, the cells were fixed by resuspending the pellet in 100 µl 
of 4 % PFA and incubating for 15 min at room temperature. After three times washing, cells 
were stored in FACS buffer until acquisition by flow cytometry (5.3).  
 
5.5 T cell-mediated tumor cell lysis assay  
 
ICOS signalling in the context of TCB-mediated T cell activation was assessed by 
T cell-mediated tumor cell lysis assay. Briefly, human PBMC were incubated with MKN45 
tumor cell line expressing the tumor antigen CEA and a titration of CEA-TCB. Therefore, 
adherent tumor target cells were harvested with Trypsin - EDTA or cell dissociation buffer, 
resuspended at a density of 105 cells per ml and 100 µl seeded to the wells of a 96-well 
flat-bottom plate (containing 104 per ml per well). Cells were left overnight at 37 °C to adhere 
to the plate. On the day of the experiment, the assay plates were centrifuged and the medium 
was aspirated. Effector cells were isolated either from human fresh blood or buffy coat (see 
5.2.2) and resuspended at 106 per ml. 100 µl of the cell suspension were added per well 
(containing 105 per ml per well), resulting in a final effector to target cell (E:T) ratio of 10:1. 
The indicated concentration of TCB was added to the corresponding wells to reach a final 
volume of 200 µl. Tumor cell lysis was assessed after 48 h of incubation by quantification of 
lactate dehydrogenase (LDH) released into the cell supernatant by apoptotic or necrotic cells 
(Cytotoxicity Detection Kit, Roche). Therefore, cells were centrifuged, 50 µl of cell medium 
were transferred to a fresh 96-well flat -bottom plate and mixed with 50 µl of catalyst - dye 
solution mix. Absorbance was measured immediately using an ELISA plate reader 
(TecanSpark 10 M). Maximal lysis of the target cells (= 100 %) was achieved by incubation 
of target cells with 1 % Triton X-100 for a minimum of 30 min before taking supernatant. 
Spontaneous lysis (= 0 %) refers to target cells co-incubated with effector cells in the absence 
of TCB.  
 
Calculation of percentage of tumor cell lysis: 
% 𝑡𝑢𝑚𝑜𝑟 𝑐𝑒𝑙𝑙 𝑙𝑦𝑠𝑖𝑠 =
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑙𝑦𝑠𝑖𝑠






5.6 T cell stimulation to study ICOS expression and signalling 
 
For stimulation of human PBMC, anti-human CD3 antibody (clone OKT3) was coated to the 
flask or assay plate at a final concentration of 0.2 - 2 g/ml by diluting the antibody in 
1 x PBS followed by either overnight incubation at 4 °C or 3 h incubation at 37 °C. 
Thereafter the antibody solution was aspirated. Human PBMC, isolated as described in 5.2.2, 
were counted, resuspended at the appropriate concentration in human T cell media and added 
to the flask or assay plate, coated with anti-human CD3 antibody. Soluble anti-human CD28 
antibody (clone CD28.2) was added at a final concentration of 2 µg/ml, followed by 
incubation of the cells for the indicated time points in a humidified incubator (37 °C, 
5 % CO2).  
 
Persistence of ICOS expression after stimulation was studied by performing a wash-out of 
anti-CD3 – anti-CD28 antibodies. Therefore, cells were transferred to a fresh assay plate, 
centrifuged and the pellet resuspended in 1 x PBS. After another centrifugation step, the 
pellet was resuspended in human T cell media followed by continued cultivation in a 
humidified incubator (37 °C, 5 % CO2). After incubation for the indicated time points, 
expression of activation markers was measured by surface staining with 25 µl of antibody 
mix containing anti-human CD45-, anti-human CD4-, anti-human CD8-, anti-human ICOS- 
and anti-human PD-1 antibody. Staining of CTLA-4 and FoxP3 was performed by 
subsequent intracellular staining. 
 
5.7 Proliferation assay 
 
Human PBMC were washed with 1 x PBS and resuspended at 106 per ml in 1 x PBS. Cell 
Trace CFSE dye (stock concentration 5 mM) was added to the cells at a final concentration of 
1 µM, mixed immediately and incubated at 37 °C for 5 min. Labelling was stopped by adding 
half the volume of pre-warmed FCS, followed by 5 min incubation to remove remaining free 
dye. After three times washing using ice-cold PBS + 10 % FCS the cell pellet was 
resuspended in T cell media. ICOS signalling studies were performed by coating a 
suboptimal concentration of 0.5 µg/ml anti-CD3 antibody as well as the indicated 
concentration of ICOS antibody to the surface of an assay plate. CFSE+ cells were seeded at 




antibodies and incubated for 5 days in a humidified incubator (37 °C, 5 % CO2). Thereafter, 
supernatant was removed; cells were washed and stained with 25 µl of antibody mix 
containing anti-human CD45-, anti-human CD4-, anti-human CD8 and anti-human ICOS 
antibody. Proliferation was measured by dilution of CFSE signal using flow cytometry. 
 
5.8 Cell based co-culture assay 
 
ICOS signalling in the context of TCB-mediated T cell activation was assessed in a cell 
co-culture assay. Therefore, adherent tumor target cells and target cells for crosslinking (e.g. 
3T3-hFAP cells) were harvested with Trypsin - EDTA or cell dissociation buffer, irradiated 
with 5000 RAD and resuspended at 105 cells per ml. 100 µl of the tumor target cells and 
100 µl target cells for crosslinking were seeded to the wells of a 96-well flat-bottom plate 
(containing 2 x 104 cells per well). Cells were incubated overnight at 37 °C to adhere to the 
plate. The day of the experiment, the assay plate was centrifuged and the medium was 
aspirated. 50 µl of targeted-ICOS antibodies were added to the adherent target cells at the 
indicated concentrations (range of 1.6 pM – 5000 pM) together with 50 µl of a fixed, 
suboptimal concentration of TCB. As controls, wells containing only the TCB molecule or 
only the targeted-ICOS antibodies were included. Effector cells, isolated either from human 
fresh blood or buffy coat (see 5.2.2), were resuspended at 106 per ml. 100 µl of the cell 
suspension (containing 105 cells per well) were added per well to obtain a final E:T ratio of 
5:1. T cell activation was assessed after 48 h incubation in a humidified incubator (37 °C, 
5 % CO2) by flow cytometric analysis, using antibodies recognizing the T cell activation 
markers CD69 (early activation marker) and CD25 (late activation marker). If differentiation 
of memory T cells was analysed, cells were incubated for a total of 72 h and surface staining 
of the T cell differentiation markers CD45RO and CCR7 was performed. 
 
5.9 Cytokine analysis  
 
For cytokine analysis from supernatant, cell based co-culture assay plates were incubated for 
72 h, centrifuged and supernatant transferred to a fresh plate. If not measured immediately, 
supernatant was stored at - 20 °C for a maximum of 3 months. Detection of several cytokines 
from supernatant was performed using the bead based Mulitplex Kits (BioRad) following the 




incubated with 50 µl of cell culture supernatant, followed by detection using biotinylated 
detection antibodies. After addition of the reporter streptavidin-phycoerythrin conjugate 
(SA-PE), beads can be sorted and analysed by measuring fluorescence intensities. 
 
5.10 Single cell RNA sequencing (scRNAseq) 
 
Next generation sequencing was used to analyse genome wide expression of cell samples on 
a single cell level. Therefore, cells were sorted for CD45+ viable cells (using FACS Aria) and 
a total of 6 x 103 cells were further processed to have full library coverage. Following the 
10x Genomics Chromium Single Cell 3`Reagent Kit protocol the partitioning of cells in 
nanolitre-scale Gel Bead-In-EMulsions (GEMs), RNA isolation, reverse transcription of 
DNA (cDNA), as well as amplification of cDNA was performed. For generation of the 
sequencing library PCR-amplified cDNA got enzymatically fragmented and random-primed 
following the protocol by 10x Genomics. Sequencing of the library was performed by ETH 
Zurich. Bioinformatic analysis was conducted with the help of the PS-BiOmics group at the 
Roche Innovation Center Basel using UMAP algorithm. In brief, the count matrix was 
analysed using Python. All data were corrected for total counts, data dimensionality reduced 
by principal component analysis. Gene set analysis was done using Enrichr server 
(http://amp.pharm.mssm.edu/Enrichr). 
 
5.11 Statistical analysis 
 
All data are presented as median +/- standard deviation (SD). Statistical analyses were 
performed using GraphPad Prism 6 (GraphPad Software). The statistical significance of 
differences was determined using the indicated statistical test. P values < 0.05 were 
considered as significant and indicated with asterisks (ns = P > 0.05; * = P ≤ 0.05; 






6.1 Assessment of ICOS and ICOSL expression on tumor and healthy donor 
peripheral immune cells 
 
The expression of ICOS and ICOSL on various immune cell subsets was investigated by 
scRNAseq on tumor-infiltrating lymphocytes (TIL) from untreated melanoma metastases and 
autologous peripheral blood (as described 5.10). As shown in the tSNE plots in Figure 4, the 
expression of ICOS was exclusively found to be on CD3+- T cells from tumor, while very 
low to no ICOS expression could be identified on autologous blood T cells. ICOSL 
expression is absent on T cells but could be detected on myeloid cells, B cells and DC from 
tumor and autologous peripheral blood in equal frequencies. 
 
 
Figure 4: Analysis of ICOS and ICOSL expression on immune cells derived from melanoma metastases 
or autologous peripheral blood cells. scRNAseq was performed on viable, CD45+ sorted immune cells from 
melanoma patient tumor (A) or autologous blood samples (B). Two-dimensional tSNE plots showing the 
clustering of immune cell subsets (top) and the distribution of ICOS+ and ICOSL+ cells among immune cell 
clusters (bottom). A total of seven patients were analysed; shown is the overlay of all seven patient samples. 
 
To study if the increased ICOS expression on melanoma metastases T cells is applicable to 
various tumor indications, ICOS expression was assessed on tumor-derived CD4+- and 
CD8+- T cells of melanoma, colorectal cancer, gastric cancer, pancreatic cancer patients as 




ICOS+ cells was detected on human tumor-derived T cells compared to T cells from healthy 
donor PBMC (Figure 5). The increased frequency ICOS+ tumor-derived T cells was more 
pronounced on CD8+- T cells. Healthy donor CD4+- T cells showed a broader baseline 
expression of ICOS compared to CD8+- T cells, varying from 4 % ICOS+ to 75 % ICOS+ 
CD4+- T cells. Overall, a high donor variability could be observed across patients regarding 
both, frequency and expression levels of ICOS+- T cells. 
 
 
Figure 5: ICOS expression on healthy donor PBMC and human TIL. Human healthy donor PBMC as well 
as human tumor infiltrating lymphocytes (TIL) derived from various tumor indications were analysed by flow 
cytometry for the frequency of ICOS+ CD4+- T cells (A) and ICOS+ CD8+- T cells (B). A total of 18 healthy 
donors and 49 patients have been tested. Each dot indicates the technical triplicate of one donor or patient. For 
statistical analysis unpaired student T-test was applied (ns = P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 
0.001; **** = P ≤ 0.0001). 
 
6.1.1 Co-expression of ICOS with other T cell immunomodulatory receptors on 
melanoma metastases TIL  
 
To further characterize the phenotype of T cells from human melanoma metastases, ICOS 
expression was compared to the expression of the co-inhibitory receptors PD-1 and CTLA-4 
on memory and naïve T cells. As shown in Figure 6, CTLA-4 and PD-1 are co-expressed 
with ICOS, both on CD4+- and CD8+- tumor-derived T cells with higher frequencies on 
memory T cells compared to naïve T cells. It was found that 50 – 60 % of human memory 
CD4+- TIL are positive for CTLA-4 and ICOS and ~ 30 % are positive for PD-1. 
Comparable frequencies of ~ 30 - 40 % CTLA-4+, ICOS+ and PD-1+ memory CD8+- TIL 
were observed. On naïve CD4+- and CD8+- T cells a frequency of ~ 20 - 30 % CTLA-4+, 
ICOS+ and PD-1+ cells was detected. Overall, the increase in frequency of CTLA-4- and 






















































ICOS- positive memory T cells was higher on CD4+- compared to CD8+- melanoma 
metastases T cells.  
 
 
Figure 6: Expression of ICOS and co-inhibitory receptors on human melanoma metastases TIL. 
Expression of CTLA-4, ICOS and PD-1 on memory or naïve CD4+- and CD8+- melanoma metastases derived 
T cells assessed by scRNAseq and depicted as frequency positive TIL. A total of seven patients was tested. Each 
dot indicates the technical triplicate of one patient. Black horizontal line indicates the mean frequency among 
the total of seven tested patients +/-SD depicted by error bars. For statistical analysis two-way ANOVA 
including Bonferroni correction was applied (ns = P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** 
= P ≤ 0.0001 
 
In summary, these findings confirm the hypothesis that tumor infiltrating T cells express the 
co-stimulatory receptor ICOS, which could therefore serve as a target for cancer 
immunotherapy.  
 
6.2 Kinetic of ICOS expression compared to other T cell immunomodulatory 
receptors 
 
Besides understanding ICOS expression on healthy and tumor-derived T cell subsets, we 
assessed the kinetics of ICOS expression in comparison to the co-inhibitory receptors 
CTLA-4 and PD-1 (Figure 7). Upon in vitro T cell stimulation of human, healthy donor 
PBMC with anti-CD3 and anti-CD28 antibodies, ICOS is rapidly upregulated on CD4+- T 
cells with a frequency of almost 80 % ICOS+ after 24 h, while ~ 20 - 30 % of CD4+- T cells 

































ICOS+ CD4+- T cells further increased to ~ 50 % CTLA-4+, ~ 75 % PD-1+ and ~ 90 % 
ICOS+ cells. Interestingly, on CD8+- T cells the kinetic of ICOS expression seemed to be 
slower as indicated by ~ 40 % ICOS+ cells after 24 h stimulation (compared to almost 80 % 
being ICOS+ CD4+- T cells after 24 h). Frequencies of CTLA-4+ and PD-1+ CD8+- T cells 
were similar to CD4+- T cells at that time point. A further increase of all receptors on CD8+- 
T cells was detected after 48 h, resulting in ~ 55 % CTLA-4+, ~ 50 % PD-1, and ~ 80 % 
ICOS+ CD8+- T cells. Overall, T cell stimulation with anti-CD3 and anti-CD28 antibody 
results in comparable expression of ICOS as well as CTLA-4 on CD4+- and CD8+- T cells, 
while PD-1 is higher expressed on CD4+- T cells.  
 
In a second step, the persistence of expression in the absence of T cell stimulus was 
investigated. Therefore, a wash-out of anti-CD3 and anti-CD28 antibodies was performed, 
followed by further incubation of the pre-stimulated PBMC in culture media. Interestingly, 
the frequency of ICOS+ CD4+- and CD8+- T cells remained stable while a time-dependent 
decline of PD-1+ and CTLA-4+ T cells was detected.  
 
 
Figure 7: Kinetic of ICOS expression on human T cell subsets in comparison to the immunomodulatory 
receptors CTLA-4 and PD-1. Human PBMC were stimulated with plate-coated anti- CD3 (1 µg/ml) and 
soluble anti-CD28 (2 µg/ml) for a total of 48 h, followed by a wash-out and continued cultivation for another 
48 h. Expression of the T cell molecules CTLA-4 (green), ICOS (red) and PD-1 (blue) was investigated by flow 
cytometry and is shown as percentage positive cells among CD4+- (A) and CD8+- T cells (B). A total of three 
independent experiments was performed in three replicates. Representative data of one experiment is shown as 
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6.3 ICOS expression upon various CD3-TCR stimulation on healthy donor T cells  
 
Knowing that ICOS is expressed on the majority of human TIL and can be induced upon 
classical TCR engagement with anti-CD3 and anti-CD28 antibody, we wanted to characterize 
the role of ICOS co-stimulation in combination with TCB-mediated T cell activation. 
Therefore, we studied the expression of ICOS upon TCB treatment and compared it to 
classical TCR stimuli on healthy donor T cells.  
 
6.3.1 TCB induces ICOS expression in a concentration dependent manner  
 
Tumor cell lysis, detected by release of LDH, could be detected upon increasing 
concentrations of CEA-TCB. Moreover, the frequency of CD69- (early activation marker) 
and CD25- (late activation marker) positive T cells increased in a CEA-TCB 
concentration-dependent manner (Figure 8B). Likewise, ICOS was induced in a CEA-TCB 
concentration-dependent manner on human T cells. Upon saturating concentration of 
CEA-TCB comparable frequency of 80 – 90 % ICOS+ cell among CD4+- and CD8+- T cell 
could be detected. 
 
 
Figure 8: TCB induces tumor cell lysis and T cell activation in a concentration-dependent manner. 
MKN45 tumor cells expressing CEA were incubated with human PBMC effector cells (E:T of 10:1) and a 
titration of CEA-targeting TCB for 48 h. (A) Tumor cell lysis detected by LDH release after 48 h incubation (B) 
T cell activation indicated by the percentage of CD25 (grey), CD69 (black) or ICOS (red) surface expression 
among CD4+- and CD8+- T cell subsets after 48 h incubation time. A total of three independent experiments 


















































































6.3.2 ICOS expression at baseline and upon CD3-TCR stimulation on effector and 
regulatory T cells  
 
As ICOS is described to be expressed on Treg cells already at baseline (see 3.3), we wanted 
to better understand the role of ICOS expression on Treg cells compared to CD4+- and 
CD8+- effector T cells in the context of CD3-TCR complex stimulation. Moreover, we were 
interested, if the observed ICOS expression pattern among the different T cell subsets is a 
general finding or specific for the activation of T cells with the TCB. Human PBMC from 
healthy donors were therefore stimulated with a saturating concentration of anti-CD3 and 
anti-CD28 antibodies or with a saturating concentration of a medium and a high potency 
CEA-TCB.  
 
As depicted in Figure 9 A, on freshly isolated human PBMC (grey squares) the expression of 
ICOS was highest on Treg cells with ~ 60 % ICOS+-Treg cells, followed by ~ 20 % ICOS+ 
CD4+- T cells and ~ 10 % ICOS+ CD8+- T cells. However, upon stimulation of T cells either 
with anti-CD3 - anti-CD28 antibodies or with CEA-TCB, ICOS is strongly upregulated on all 
T cell subsets with highest frequency on Treg cells (~ 90 - 100 %) followed by comparable 
frequencies of ICOS+ CD4+- and CD8+- T cells. Higher ICOS expression could be detected 
upon co-stimulation using the high potency CEA-TCB suggesting that stronger T cell 






Figure 9: ICOS expression is increased on various stimulated T cell subsets. ICOS expression on human T 
cell subsets at baseline and upon activation for 48 h with anti-CD3 - anti-CD28 or CEA-TCB. Healthy donor 
PBMC either untreated, cultured in vitro with anti-CD3 (1 g/ml) - anti-CD28 (2 g/ml) or upon crosslinking of 
T cells and target cells using a saturating concentration of human medium potency and high potency CEA-TCB. 
Shown is the Frequency (%) of ICOS expression. A total of seven independent experiments on healthy donor 
samples was performed in three replicates. For statistical analysis two-way ANOVA using Bonferroni 
correction was applied (ns = P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001). 
 
6.4 ICOS signalling depends on crosslinking and CD3 co-stimulation  
 
ICOS signalling naturally occurs upon ligation of the ICOS receptors with its ligand ICOSL, 
causing the intracellular activation of the PI3K-Akt pathway, consequently resulting in 
enhanced T cell proliferation. To better understand the requirements for efficient ICOS 
downstream signalling, human T cells were stimulated with an agonistic ICOS IgG antibody 
in the presence or absence of a suboptimal anti-CD3 trigger and effects on the proliferation 
was analysed. The ICOS antibody was either administered in solution or bound to the plate 
(crosslinked). Figure 10 shows that simultaneous stimulation with anti-CD3 and anti-ICOS 
agonistic antibody led to increased T cell proliferation only if the ICOS antibody was 
crosslinked (blue bar). Addition of the ICOS antibody in solution does not induce further 
proliferation of T cells compared to CD3 alone (red bar). Moreover, the data shows that 
ICOS signalling depends on a concurrent TCR engagement. In the absence of anti-CD3 

































Figure 10: ICOS signalling requires concurrent CD3 signalling and crosslinking. T cell proliferation 
measured by CFSE dilution after 5 days stimulation with 0.5 µg/ml of anti-CD3 (clone OKT3) +/- anti-ICOS 
agonistic antibody either crosslinked (x-link) by coating the antibody to the bottom of the assay plate or added 
in solution. Shown are histograms of proliferation peaks and x-fold increase proliferation of human CD4+- and 
CD8+- T cells. T cell proliferation based on T cell counts were normalized to untreated cells (bar chart). A total 
of two independent experiments was performed in three replicates. Data is shown as mean +/- SD. For statistical 
analysis one-way ANOVA was applied using Dunnett`s multiple comparison (ns = P > 0.05; * = P ≤ 0.05; 
** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001). 
 
6.5 Generation of novel, agonistic ICOS antibodies  
 
An agonistic ICOS antibody needs to fulfil two criteria to induce significant ICOS 
downstream signalling: (i) a concurrent TCR signal and (ii) the need crosslinking. Based on 
this, two targeted formats of anti-ICOS antibodies were cloned, produced and purified (as 
described in 5.1). A schematic structure of the antibodies is shown in Figure 11.  
The described ICOS binding antibodies comprised an anti-human ICOS binding domain and 
a crosslinking domain that binds to a tumor-associated stroma antigen (hereafter referred to 
as stroma-target). As a control for crosslinking, ICOS binding antibodies comprising an 
untargeted control binding domain were generated.  
 
The so called 1 + 1 format consisted of one fragment antigen binding (Fab) directed against 
ICOS and another Fab against the tumor-associated stroma target or the untargeted control 






































































































































































crosslinking domain. Bivalent ICOS binding was provided by the so called 2 + 1 formats. 
These antibodies contained two ICOS binding Fabs and a c-terminal Fc fused VH/VL against 
the stroma target or the untargeted control binding domain (Figure 11, C, D). All ICOS 
antibodies used in this work carried the P329GLALA mutation in the Fc part (Schlothauer et 
al., 2016), which prevents binding to the Fc receptor (called silent Fc).  
 
 
Figure 11: Schematic view of various targeted, agonistic anti-human ICOS antibodies. Targeted anti-ICOS 
antibodies, binding the human ICOS receptor and a targeting moiety, were cloned and produced either as 
monovalent 1 + 1 format or as bivalent 2 + 1 format. (A) stroma-targeted ICOS 1 + 1 (B) untargeted-control 
ICOS 1 + 1 (C) stroma-targeted ICOS 2 + 1 (D) untargeted-control ICOS 2 + 1. All shown antibodies carry a 
P329GLALA mutation in the Fc part (silent Fc). 
 
All antibodies were produced by transiently transfecting HEK293EBNA cells and purified 
from cell culture supernatant by SEC and Protein A chromatography. The purity of the final 
product, including molecular weight, aggregate content as well as heat stability of the 
antibodies, was tested by the Process Biochemistry group of Roche Innovation Center Zurich. 
 
6.5.1 Binding of targeted ICOS antibodies to cells 
 
The binding of several targeted anti-ICOS constructs was tested on cell lines generated to 
overexpress either the human ICOS receptor or the stroma-target antigen (see 5.4). Human 
ICOS antibodies specifically bound to human ICOS (Figure 12, A) in a 
concentration-dependent manner. Moreover, ICOS binding was comparable for the 
monovalent and the bivalent ICOS antibodies. Specific binding to the stroma-target antigen 
was given for the stroma-targeted constructs, irrespective of the 1 + 1 or 2 + 1 format (Figure 
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Figure 12: Percentage binding of human anti-ICOS antibodies to cells expressing ICOS or cells 
expressing the stroma target antigen. For binding analysis, (A) Chinese hamster ovary (CHO) cells 
expressing human ICOS and (B) 3T3 cells expressing the human stroma target antigen were incubated with a 
titration of targeted anti-human ICOS antibodies. Binding of antibodies was detected using a secondary, 
fluorophore-conjugated anti-human Fc antibody and is depicted as frequency positive cells (%). A total of two 
independent experiments was performed in three replicates and shown as mean +/- SD.  
 
6.6 ICOS signalling enhanced TCB-mediated T cell activity 
 
In a next step, we wanted to address how the human agonistic anti-ICOS antibodies can 
further boost CEA-TCB-mediated T cell activation in a cell based co-culture assay. 
Therefore, human PBMC were stimulated with a sub-optimal CEA-TCB concentration of 
0.2 nM. Besides inducing ICOS expression (Figure 13), a sub-optimal CEA-TCB 
concentration ensured the sub-optimal activation of T cells that could be further amplified by 
ICOS co-stimulation.  
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Figure 13: ICOS expression upon CEA-TCB-mediated T cell stimulation. Healthy donor PBMC were 
co-cultured with CEA-positive tumor cells, fibroblasts and stimulated with 0.2 nM CEA-TCB. (A) Histogram 
showing an overlay of ICOS surface expression peaks on CD4+- T cells (A) and CD8+- T cells (B) either 
unstimulated (unfilled peak) or after 48 h incubation with TCB (turquoise peak). A total of three independent 
experiments was performed in three replicates. Representative histogram of one donor is shown. 
 
To determine the effect of ICOS co-stimulation, T cell activation after 48 h incubation of 
CEA-TCB stimulated cells in the presence or absence of a titration of stroma-targeted or 
untargeted control ICOS antibody was assessed by FACS analysis. Addition of 
stroma-targeted ICOS antibodies, either in the 2+1 or the 1+1 format, led to a 
concentration-dependent increase in expression of the T cell activation marker CD25 on both 
CD4+- and CD8+- T cells (Figure 14). The observed, concentration-dependent T cell 














































Figure 14: T cell activation upon ICOS co-stimulation in combination with CEA-TCB treatment. Healthy 
donor PBMC were co-cultured with tumor cells and fibroblasts, stimulated with 0.2 nM CEA-TCB in the 
presence or absence of a titration of stroma-targeted or untargeted control ICOS antibody. Surface expression of 
T cell activation marker CD25 was measured after 48 h incubation by FACS analysis. Median fluorescence 
intensity (MFI) of CD25 among CD4+- (A) and CD8+- T cells (B) is shown. A total of three independent 
experiments was performed in three replicates. Representative data of one experiment is shown as mean +/- SD. 
Significant differences were analysed by two-way ANOVA including Bonferroni correction (ns = P > 0.05; * = 
P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001). 
 
ICOS co-stimulation is also described to play an important role in T cell differentiation, 
including formation of memory T cell activation (Smith et al., 2003). Consequently, after 
72 h incubation we investigated the frequency of naïve (CD45RO-, CCR7+), central memory 
(Tcm, (CD45RO+, CCR7+)), effector memory (Tem, (CD45RO+, CCR7-)) and effector 
memory RA+ (Temra, (CD45RO-, CCR7-)) T cells. Upon co-stimulation with the 
stroma-targeted or the untargeted control ICOS antibodies in the 1 + 1 format an increase in 
the CD4+- and CD8+- Tcm cell population compared to CEA-TCB only treated cells could 
be detected. Moreover, ICOS co-stimulation with the monovalent ICOS antibodies resulted in 
decreased frequency of CD4+- Tem cell population, while a higher frequency of CD8+- Tem 
cells was found.  
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Figure 15: Memory T cell differentiation upon ICOS co-stimulation with CEA-TCB treatment Healthy 
donor PBMC were co-cultured with tumor cells and fibroblasts, stimulated with CEA-TCB (0.2 nM) and 
stroma-targeted or untargeted control ICOS 1+1 (1 nM) antibody. T cell differentiation after 72 h incubation is 
shown as FACS dot plot displaying the gating on naïve (CD45RO-, CCR7+)), central memory (Tcm 
(CD45RO+, CCR7+)), effector memory (Tem (CD45RO+, CCR7-)) and effector memory RA (Temra 
(CD45RO-, CCR7-)) T cells subsets. Frequency of memory T cell subsets upon treatment with CEA-TCB, 
CEA-TCB + stroma-targeted ICOS 1 + 1 antibody or CEA-TCB + untargeted-control ICOS 1 + 1 antibody is 
shown. A total of three independent experiments was performed. Representative data of one donor is shown. 
 
The observed co-stimulatory effect of the ICOS antibodies in T cell differentiation was 
independent of the antibody format. A decrease in naïve T cell counts accompanied by an 
increase in CD4+- and CD8+-Tcm cell counts could be detected upon addition of the 
stroma-targeted ICOS antibody formats. Likewise, the untargeted-control ICOS antibodies 
resulted in increased Tcm cell count (Figure 16). Still, the number of cells undergoing 







Figure 16: Memory T cell counts upon ICOS co-stimulation with- CEATCB treatment Healthy donor 
PBMC were co-cultured with tumor cells and fibroblasts, stimulated with CEA-TCB (0.2 nM) and stroma-
targeted or untargeted control ICOS antibody. T cell differentiation after 72 h incubation is shown as a bar chart 
depicting the x-fold increase of naïve (Tn (CD45RO-, CCR7+)), central memory (Tcm (CD45RO+, CCR7+)), 
effector memory (Tem (CD45RO+, CCR7-)) and effector memory RA (Temra (CD45RO-, CCR7-)) T cells 
counts. Values are normalized to cell counts upon CEA-TCB only treated cells. Change in cell counts among the 
different T cell populations upon treatment with stroma-targeted or untargeted-control ICOS antibody formats is 
shown. A total of three independent experiments was performed in three replicates. Representative data of one 
experiment is shown as mean +/- SD. Significant differences were analysed by two-way ANOVA including 
Bonferroni correction (ns = P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001). 
 
The synergy of the combination of CEA-TCB and ICOS agonism was also evidenced by 
increased cytokine secretion. Maximal cytokine values upon co-stimulation with the various 
targeted-ICOS antibodies after normalization to the level of cytokines induced by treatment 
with CEA-TCB only are shown in a heat map (Figure 17). Addition of the stroma-targeted 
ICOS antibodies resulted in enhanced cytokine secretion compared to untargeted-control 
ICOS antibodies. Interestingly, differences in the pattern of cytokine secretion could be 
observed between the stroma-targeted ICOS antibody formats. While the monovalent ICOS 
antibody format was significantly enhancing the secretion of IL-13, IL-17A, IL-5, and IL-6, 
the bivalent stroma-targeted ICOS antibody resulted in an increased secretion of GM-CSF, 
IFN-γ, IL-10, IL-2 and TNF-α. As seen in T cell differentiation the untargeted-control ICOS 
antibody in the 2 + 1 format showed weak baseline activation, indicated by a moderately 
increased secretion of the cytokines IFN-γ, IL-2, IL-4, and TNF-α compared to CEA-TCB 
only. 
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Figure 17: Cytokine secretion upon ICOS co-stimulation with CEA-TCB treatment Healthy donor PBMC 
were co-cultured with tumor cells and fibroblasts, stimulated with CEA-TCB (0.2 nM) and stroma-targeted or 
untargeted control ICOS antibody (1 nM). Secreted cytokines from cell culture supernatant after 72 h incubation 
were analysed by bead-based multi-parametric assay. A total of three independent experiments was performed 
in three replicates. Representative maximal cytokine values (max value) of one donor after normalization to 
cytokine values upon incubation with CEA-TCB only are displayed. The color code of the heatmap was 
generated using the GraphPad Prism algorithm and indicates the range of normalized cytokine values. For each 
of the depicted cytokines the range varies from maximal (max) cytokine values (red) to minimal (min) cytokine 
values (blue).  
 
Based on these data, no clear format ranking of the various, targeted-ICOS antibodies could 
be done. Both formats of the stroma-targeted ICOS antibody equally increased 
TCB-mediated T cell activation and depended on crosslinking. For T cell differentiation no 
major difference in format could be detected. The only format difference was identified 






6.7 Single cell RNA sequencing analysis of regulated genes upon ICOS combination 
therapy 
 
To gain a deeper understanding of genes and pathways altered in T cells as well as secondary 
effects on other immune cells upon ICOS co-stimulation, we performed a transcriptome 
analysis on single cell level of human PBMC co-cultured with tumor cells and treated in vitro 
with TCB alone or in combination with stroma-targeted ICOS antibody (described in 5.8 and 
5.10).  
 
As shown in previous experiments, the optimal time for detecting ICOS combination effects 
on T cells by FACS analysis was 40 – 48 h. Therefore, human PBMC either cultured in vitro 
with TCB alone, in combination with stroma-targeted ICOS antibody or without stimulus, 
were harvested after 42 h incubation.  
 
Analysis of the scRNAseq data was done with the help of Petra Schwalie from the 
PS-BiOmics group at the Roche Innovation Center Basel. The clustering of all sequenced 
cells summarized in a two-dimensional UMAP plot is shown in Figure 18 A. Displaying the 
clustering by treatment groups (Figure 18 B) revealed a locational change from untreated 
cells (untreated) towards cells that were stimulated with TCB alone (TCB) and cell 
stimulated with TCB + stroma-targeted ICOS antibody (TCB + ICOS). Cells of the TCB or 
TCB + ICOS treatment groups were predominantly located in the memory and activation T 
cell clusters as well as the lysozyme+ myeloid cell cluster (M.LYZ). Differences in cell 
frequency among TCB monotherapy and the TCB + ICOS combination group are 
summarized in Figure 18 C, as the logarithm of ratio cell fraction. Upon combination with 
ICOS, a reduction in naïve T cells and NK cells as well as a higher frequency in the memory 
and activated CD4+- and CD8+- T cell clusters, classical CD14+ myeloid and LYZ+ myeloid 
cells could be detected. The strongest increase upon ICOS combination was observed in 






Figure 18: Single cell RNA sequencing of in vitro treated human PBMC (untreated, TCB treated (5 pM), 
TCB (5 pM) + ICOS (5 nM); incubated for a total of 42 h. 2-dimensional UMAP plot of CD45+ viable cells, 
analysed by scRNAseq. (A) Clustering of immune cell subsets based on the Louvain algorithm. (B) UMAP plot 
indicating cell distributing among the different treatment groups by color. (C) Fold change cell frequency upon 
TCB + ICOS vs. TCB indicated as log (ratio cell fraction). Experiment was performed as a single replicate on 
one donor. Analysis was performed with the help of PS-BiOmics group at the Roche Innovation Center Basel. 
 
Gene signature changes upon ICOS co-stimulation were investigated by scRNAseq. For this 
purpose, gene signatures describing the functional phenotype of cells were analysed. Based 
on the work of Singer et al. (Singer et al., 2017) this included signatures for cell activation 
(Act); cell dysfunction (Dys); both activation and dysfunction (Act/Dys); as well as naïve and 
memory cell phenotype. Shown in violin plots (Figure 19) is the distribution of cells among 
the treatment groups expressing genes that contribute to the signature. More cells with 
increased expression of genes contributing to the activation signature in CD4+- T cells, 
CD8+- T cells and B cells could be detected in the TCB + ICOS group. However, no 
significant change was discovered in the dysfunction cell signature upon ICOS 
co-stimulation. Signatures containing both, activation and dysfunction related genes were 
again higher in CD4+- T cells, CD8+- T cells and B cells.  
 
Furthermore, we were curious if gene signature changes in the known main ICOS signalling 
pathways, TBK1 and PI3K, could be detected upon combination with the agonistic ICOS 
antibody (gene signatures were received from Reactome database). On CD4+- and CD8+- T 
cells an increase in cells contributing to the TBK1 gene signature upon ICOS co-stimulation 





Figure 19: Gene signatures among treatment groups.  Sequenced cells of the different treatment groups 
(indicated by color) were analysed with the help of PS-BiOmics group at the Roche Innovation Center Basel. 
Analysis of various signalling pathways was based on published gene signatures and are displayed as Violin 
Plots. Distribution of cell activation (Act), dysfunction (Dys), activation/dysfunction (Act/Dys), as well as 
naïve/memory cell signature (based on gene signatures described by Singer et al. (Singer et al., 2017) on the 
indicated immune cell subsets. TBK1 and PI3K signatures are based on the Reactome database. Experiment was 
performed as a single replicate on one donor. Significant differences between the groups were analysed by two-
sided, non-parametric Wilcoxon signed-rank test (ns = P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01).  
 
In addition, we assessed the cytokine and chemokine pattern between the TCB monotherapy 
and the ICOS combination group. The distribution of cells expressing genes of cytokines and 
chemokines that were different between the treatment groups in analysed immune cell subsets 
is shown (Figure 20). In CD4+- T cells ICOS co-stimulation resulted in greater CCL2 and 
IFN-γ expression, while more cells with increased expression of CCL17 could be detected in 
the CD8+ cluster. Even though augmented activation signatures were discovered in B cells of 
the ICOS combination group, this could not be confirmed by higher cytokine or chemokine 
expression. In myeloid cells, more cells with higher CXCL10, CCL2, IFN-γ and IL-13 






Figure 20: Cytokine signatures among treatment groups.  Sequenced cells of the monotherapy (blue) and 
combination treatment group (orange) were analysed for altered cytokine expression of CXCL10, CCL2, IFN-γ, 
IL-13 and CCL17 with the help of PS-BiOmics group at the Roche Innovation Center Basel and are displayed as 
Violin Plots for the indicated immune cell subsets. Experiment was performed as a single replicate on one 
donor. Significant differences between the groups were analysed by two-sided, non-parametric Wilcoxon 
signed-rank test (ns = P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01).  
 
In summary, scRNAseq analysis revealed a very similar pattern between TCB treatment and 
ICOS co-stimulation. Changes upon ICOS signalling resulted in minor magnitude changes 









The present work provides insights into the expression and induction of the T cell 
co-stimulatory receptor ICOS in human healthy and tumor infiltrating immune cells. It could 
be shown by systematic analysis that ICOS is expressed on tumor T cells and is inducible on 
T cells upon simultaneous binding of a TCB to tumor cells and healthy donor T cells. For the 
first time, we studied the effect of ICOS co-stimulation in combination with TCB using 
novel, targeted agonistic ICOS antibodies. 
 
Affinity and format of bispecific antibodies can have a significant impact on the antibody`s 
therapeutic potency (Spiess et al., 2015). In contrast to co-stimulatory receptors belonging to 
the TNFR family, oligomerization of the antibody or ligand is not expected to be required for 
Ig-like superfamily members (Bodmer et al., 2002, Mayes et al., 2018). Since the natural 
ligand for ICOS is described to be expressed on the cell surface predominantly as a 
homodimer (Chattopadhyay et al., 2006), we tested the bivalent and the monovalent ICOS 
binding antibody format to see if monovalent binding to ICOS and simultaneous binding to a 
target moiety (= crosslinking) could be equally (or even more) potent.  
 
Functional assessment allowed no clear differentiation between the antibody formats. Both, 
the monovalent 1 + 1 and the bivalent 2 + 1 antibody format induced increased T cell 
activation but revealed different cytokine secretion patterns. Possible explanations are going 
to be discussed below. Nevertheless, slight unspecific activity was observed with the 
untargeted-control ICOS 2 + 1 antibody in late T cell responses, as T cell differentiation and 
cytokine secretion. Similar findings, stating a certain baseline activity of bivalent ICOS 
antibodies in the absence of crosslinking, could explain these observations (Takashi Tsuji, 
2008).  
 
7.1 ICOS expression and induction on healthy human T cells 
 
ICOS, as a member of the IgG-like superfamily, is expressed on literally all activated T cell 
subsets. Consistent with literature, we could validate that ICOS baseline expression is highest 
on Treg cells, followed by conventional CD4+- and CD8+- T cells. Likewise, this study 




upregulated on CD4+- and CD8+- effector T cells as well as Treg subsets (Beier et al., 2000, 
McAdam et al., 2000). The fast kinetic of ICOS and the persistence of ICOS surface 
expression after wash out of anti-CD3 - anti-CD28 stimulus described in 6.2, indicates an 
important role of ICOS both during early and later stages of T cell co-stimulation.  
 
The importance of ICOS co-stimulation in early stages of T cell activation is shown in a 
study of Tafuri et al. Proliferation and expression of activation markers of T cells of ICOS -/- 
mice were impaired at an early time point of 24 h stimulation, but could be recovered at 72 h 
probably by other molecules (Tafuri et al., 2001). Also others reported defective 
proliferation, effector differentiation and cytokine immune functions of T cells stimulated in 
the absence of ICOS signalling (Coyle et al., 2000, Dong et al., 2001, Nurieva et al., 2003).  
 
A growing body of literature likewise suggests the importance of ICOS signalling in T cell 
memory differentiation. Burmeister et al. reported a reduced number of CD44+ CD62L+ 
memory T cells in mice carrying a genetic knock-out for either ICOS or ICOSL (Burmeister 
et al., 2008). Human ICOS deficiency patients were reported to have a decreased CD4+ 
central and effector memory T cell compartment. Moreover, ICOS deficiency is often 
accompanied by impaired CD4+- and CD8+- effector T cell function (Grimbacher et al., 
2003, Takahashi et al., 2009). 
 
7.2  T cell subsets affected by ICOS co-stimulation  
 
The expression level of ICOS is described to correlate with a distinct cytokine expression 
pattern: Lohning et al. reported that ICOShigh cells mainly produce IL-10, ICOSmedium cells 
produce IL-4, IL-5 and IL-13 and ICOSlow cells produce IL-2, IL-6 and IFN-γ (Lohning et 
al., 2003). We showed that upon TCB treatment, ICOS expression levels were comparable on 
CD4+- as well as CD8+- T cells and slightly higher on Treg cells. Still, in vitro combination 
of TCB and ICOS agonistic antibody revealed different cytokine patterns for the monovalent 
and the bivalent ICOS antibody. Co-stimulation by the stroma-targeted ICOS 2 + 1 antibody 
resulted in increased secretion of Th1 cytokines (IFN-γ, TNF-α, GM-CSF) as well as IL-2 
and IL-10. In contrast, an enhanced secretion of Th2 cytokines (IL-5, IL-6, IL-13) and Th17 
cytokine IL-17A was detected in combination with the monovalent stroma-targeted ICOS 1 + 




agonistic ICOS antibodies cannot be correlated to the ICOS expression level. Instead, the 
various antibody formats, hence the degree of crosslinking, may result in altered intensity of 
subsequent ICOS downstream signalling. Moreover, the different antibody formats could 
cause altered cytokine kinetics. Since the cytokines have been analysed at one single point in 
time, this might also explain the differences.  
 
Even though potentially interesting, the data must be interpreted with caution because 
cytokines from supernatant were analysed, which does not allow the identification of the 
specific T cell or immune cell subset (and its differentiation or activation status) that 
produced them. Further studies focused on intracellular cytokine T cell staining as well as a 
time-dependent assessment of their secretion are needed to better understand the underlying 
mechanisms upon format difference as well as identifying the T cell subsets being most 
responsive to ICOS co-stimulation.  
 
7.3 Rationale of combining ICOS with TCB 
 
TCB are able to tackle some immune escape mechanisms. Upon simultaneous binding of a 
tumor antigen and the CD3ɛ chain, TCB treatment represents an option of MHC-independent 
T cell activation, thereby overcoming lack of tumor- immunogenicity and T cell tolerance. 
Strong ICOS signalling is dependent on a concurrent first T cell signal. This implies the 
necessity of a tumor-inflamed setting. TCB-specific recruitement of T cells to the tumor site 
allows the transformation of poorly infiltrated or immune excluded tumors into inflamed 
tumors (Bacac, Klein, et al., 2016).  
 
In this study, it could be demonstrated that both, a classical anti-CD3 and anti-CD28 
stimulation as well as TCB are able to induce ICOS expression. This finding is in line with 
recently published data by Bacac et al. showing that in vitro stimulation of human PBMC 
with anti-CD20-TCB likewise results in a time-dependent up-regulation of ICOS on human T 
cells (Bacac et al., 2018). Therefore, up-regulation of ICOS is more a general consequence of 
TCB-mediated activation of T cells. Combining TCB treatment with tumor-targeted ICOS 
antibodies consequently could broaden the field of possible tumor indications applicable to 
ICOS co-stimulation. In addition to the up-regulation of ICOS, TCB treatment also induces 




the anti-tumor T cell response (Bacac, Klein, et al., 2016). However, it was shown that TCB 
response can be enhanced by blocking the co-inhibitory receptor PD-1 expressed on activated 
T cells. Another promising approach of boosting T cell activity is the engagement of 
co-stimulatory receptors, for instance by combining TCB treatment with an agonistic ICOS 
antibody.  
Providing additional co-stimulatory signal by an agonistic ICOS antibody to TCB treated 
cells can help in obtaining long-term protection by ICOS-mediated T cell memory formation 
(Burmeister et al., 2008, Mahajan et al., 2007, Marriott et al., 2015, Moore et al., 2011). 
T cell activation without or with weak co-stimulation is reported to induce T cell anergy, a 
state of T cell unresponsiveness (Crespo et al., 2013). ICOS co-stimulation could enhance 
TCB-mediated T cell response and potentially rescue TCB-treated T cells from anergy 
(Nurieva et al., 2006).  
 
7.4 Safety aspects of ICOS co-stimulation  
 
7.4.1 Superagonism upon ICOS co-stimulation  
 
Overstimulation of the immune system as occurred in 2006 during a Phase I clinical trial with 
the super-agonistic CD28 antibody TGN1412 cautions use of agonistic antibodies in human. 
TGN1412 was capable of activating CD28 irrespective of concurrent TCR activation, with 
the result of severe cytokine release syndrome and multiple organ dysfunctions (Hunig, 
2016). Considering the structural and functional similarity of ICOS and CD28, the necessity 
of a concurrent CD3 signal and crosslinking of the antibody to ensure optimal ICOS 
signalling implies an important safety aspect. Reliance of ICOS signalling on concurrent 
TCR stimulation is in agreement with data previously published in a patent by Sazinsky et al. 
as well as reported by Wakamatsu et al. (Sazinsky, 2016, Wakamatsu et al., 2013). 
 
Crosslinking naturally occurs by receptor-ligand interactions delivered by T cell to APC 
engagement. Artificially mimicking this natural cell-cell contact for antibody based 
approaches can be achieved by introducing a crosslinking binding site (Mayes et al., 2018). 
Besides providing full downstream signalling, a tumor-associated crosslinking target enables 




immunotherapeutic agent is ABBV-428, a bispecific antibody targeting CD40 and a 
tumor-associated antigen (Dahlen et al., 2018).  
 
7.4.2 Risk of targeting ICOS+-Treg cells 
 
As mentioned earlier, Treg cells are characterized by high baseline expression of ICOS 
expression. Stimulation of ICOS+-Treg cells with an agonistic antibody involves the risk of 
tumor-promoting, immunosuppressive T cell response.  
 
Looking at the preclinical and clinical landscape, two key paradigms of ICOS agonistic 
antibodies can be described (shown in Figure 2): the first generation of agonistic antibodies 
usually exhibit a wild-type Fc, enabling the simultaneous binding to ICOS+- T cells and FcR 
positive cells, as NK cells or macrophages. Since the expression of ICOS on Treg at baseline 
is higher than the one on Teff cells, this is expected to result in a preferential depletion of 
ICOShigh Treg cells. This is a mode of action that is described for JTX-2011, a dual activity 
ICOS agonistic antibody designed to stimulate T eff cells and deplete intratumoral Treg cells. 
The hypothesis of how the two mechanisms can coincide is based on the different ICOS 
expression density among Teff and Treg subsets as well as on receptor occupancy (Mayes et 
al., 2018). The appropriate tumor indication with a favorable Teff to Treg ratio at baseline 
needs to be chosen accordingly. For instance cancer indication with high ICOS+-Treg 
infiltration (non-small cell lung cancer, head and neck squamous cell carcinoma) are well 
applicable to JTX-2011 ICOS+-Treg depletion mechanism (Sazinsky, 2016).  
The second generation of agonistic ICOS antibodies usually comprises an ICOS- as well as a 
second targeting moiety that is used to crosslink the molecule. Here, the Fc part is usually 
modified to prevent any Fc-FcR interaction. One such example is the ICOS PD-L1 bispecific 
human IgG1 antibody that activates ICOS signalling through bridging together ICOS- and 
PD-L1-expressing cells. In a CT26 tumor model it was reported that the depletion of ICOShigh 
Treg cells together with an improved Teff : Treg ratio (Sainson et al., 2018). 
 
TCB treatment results in an increased recruitement and proliferation of CD4+- and CD8+- 
effector T cells in the tumor microenvironment, but also increases the ratio of Teff to Treg in 
TIL upon therapy (Bacac, Fauti, et al., 2016). According to this, we could confirm upon in 




and CD8+- effector T cells. Despite the higher ICOS expression level detected on human 
Treg, the combination with a TCB therefore allows the treatment with an agonistic ICOS 
antibody since starting numbers of Teff are higher than Treg. 
 
7.5 ICOS co-stimulation in TCB-mediated anti-tumor efficacy 
 
By scRNAseq transcriptome analysis we wanted to get more insight at a single cell level on 
the co-stimulatory effects of ICOS not only on T cells but also on other immune subsets that 
orchestrate anti-tumor immunity. Overall, gene signatures and cell frequency counts upon 
TCB monotherapy or in combination with ICOS agonistic antibody were very similar. Even 
though only a small percentage of cells responded to ICOS co-stimulation, transcriptome 
analysis could confirm results obtained from our previous in vitro experiments or being 
described for ICOS signalling. A slight decrease of naïve cells upon co-stimulation and an 
increase in activated and differentiated T cells could be observed based on cell frequency 
counts and signature distribution (Burmeister et al., 2008, Okamoto et al., 2004, Singer et al., 
2017). 
 
Signalling pathway gene signature of ICOS co-stimulation and TCB seem to be similar. Both 
treatments similarly activated genes contributing to the main ICOS signalling pathway PI3K 
(Hutloff et al., 1999). Surprisingly, on CD4+- and CD8+- T cells an increase in cells 
contributing to the TBK1 gene signature could be detected upon ICOS co-stimulation. Using 
a suboptimal TCB concentration for combination assays this finding is in contrast to 
literature, describing the stringent dependency on a concurrent strong CD3 stimulus for 
activation of the TBK1 pathway (Pedros et al., 2016).  
 
From a technical point of view, one has to bear in mind that even though ICOS-mediated 
co-stimulation can be detected after 42 h in vitro stimulation by increased T cell activation, 
this might not be the optimal timepoint for detection of gene signature changes. Signalling 
pathways, as PI3K, are early events of T cell activation implying a kinetic study to reveal the 
optimal timepoint to allow gene signature changes by scRNAseq.  
 
Conclusively, one can assume that ICOS co-stimulation rather enhances the magnitude of the 




consideration that the analysis was performed on one donor and at one time point only, this 
conclusion needs to be validated by more repetitions and with more exhaustive and time-
dependent analysis to also take into account interindividual variability.  
 
7.6 Combination of ICOS signalling and checkpoint blockade 
 
T cell activation is a dynamic and flexible procedure of adaptive immune response driven by 
T cell co-stimulatory and co-inhibitory receptors. Positive and negative signals might be 
triggered on the same cell either simultaneously or consecutively. This contributes to the 
complexity of fully understanding T cell-mediated anti-tumor response.  
 
Both, CTLA-4 and PD-1 mediate immune inhibition, but with different timing and anatomic 
location. CTLA-4 is known to regulate T cell proliferation early during the priming phase of 
immune response in lymphoid tissues, PD-1 preferentially functions during late effector 
phase on T cells within peripheral tissues. This diverse role is believed to be the reason for 
the success in combining checkpoint inhibitors against both pathways and thereby blocking 
early and late T cell inhibition (Mahoney et al., 2015, Wei et al., 2017). The co-expression of 
ICOS with PD-1 and CTLA-4 on activated healthy as well as on tumor-derived T cells 
detected in this study is in accordance with reports by other groups (Liu, 2016, Sazinsky, 
2016) and provides the rationale for combining immune checkpoint inhibitors with ICOS 
co-stimulation.  
 
Tang et al. detected elevated ICOS levels on blood T cells after anti-CTLA-4 therapy in 
melanoma and bladder cancer patients (Ng Tang et al., 2013). This was followed by showing 
agonistic effects of ICOS activation in combination with anti-CTLA-4 therapy in a preclinical 
mouse model of melanoma and pancreatic cancer. Interestingly, combining ICOS 
co-stimulation with CTLA-4 therapy resulted in an increased Teff to Treg ratio (Fan et al., 
2014, Fu et al., 2011). A similar finding was published by Zamarin et al. increasing CTLA-4 
blockade by ICOS co-stimulation by using an oncolytic Newcastle disease virus expressing 
ICOSL. It is essential to point out that upon intra-tumoral therapy with ICOSL expressing 
virus, they could show that ICOS co-stimulation not only affects the tumor locally, but can 




strengthens our hypothesis of the generation of tumor-reactive, long-lived memory cells upon 
ICOS agonism.  
 
A growing body of combinations using co-stimulatory antibodies together with PD-1 - PD-L1 
blocking antibodies highlight the beneficial disease outcome potential (Hu-Lieskovan et al., 
2017). Two examples of ICOS antibodies currently being tested in combination with PD-1 
blockade entered the clinics in 2016. The combination of agonistic ICOS IgG4 antibody 
GSK-3359609 with pembrolizumab is tested in different solid tumor indications (Liu, 2016). 
Moreover, advanced-stage solid tumors were tested with the combination of JTX-2011 ICOS 
agonistic IgG1 antibody with the PD-1 blocking antibody nivolumab (Mayes et al., 2018). 
While GSK-3359609 acts as a true agonist, the JTX-2011 unifies Fc-mediated ADCC and 
agonistic properties. First data are expected in 2020 for both studies. Moreover, pre-clinical 
investigation of simultaneous binding to ICOS and PD-1 using a bispecific antibody resulted 
in an improved intra-tumoral Teff : Treg ratio (Sainson et al., 2018).  
 
Taking together the above given examples of successfully combining ICOS with checkpoint 
inhibition and given that ICOS is expressed along with PD-1 and CTLA-4 upon TCB 
stimulation, provides rationale for combining TCB treatment with the herein described 
agonistic ICOS antibodies and immune checkpoint inhibition. 
 
7.7 Role of ICOS signalling in regard to tumor progression 
 
Elevated ICOS expression levels on TIL compared to autologous as well as healthy donor 
PBMC were detected in this study, also stated by others (Sainson et al., 2018, Sazinsky, 
2016) . Several, contradicting reports on the correlation of ICOS expression and tumor 
outcome are published. A positive correlation of increased ICOS expression on primary 
tissue T cells and overall survival in untreated colorectal cancer patients was reported by 
Zhang et al (Zhang et al., 2016). In contrary, a poor prognosis correlates with tumor 
infiltration of ICOS+- T cells in primary breast cancer patients, based on the proliferation of 
ICOShigh Treg cells upon interaction with ICOSL+ plasmacytoid DCs (Faget et al., 2013). 
Similarly, a study by Martin-Orozco et al. shows that ICOSL expression on melanoma cells is 




et al., 2010). It is thus envisionable that ICOS agonisation might induce detrimental effects to 
the cancer patient. This needs to be kept in mind while further evaluating this approach. 
 
7.8 Outlook  
 
In summary, this study showed that ICOS co-stimulation using novel agonistic, 
tumor-targeted antibodies has the potential to boost T cell activation. Current literature 
provides evidence that ICOS co-stimulation can fuel anti-tumor efficacy. As indicated before, 
the dynamics of the adaptive immune system manifests a time-dependent administration of 
co-stimulatory and co-inhibitory molecules. Further, in-depth investigation is needed to better 
understand the underlying mechanisms of ICOS co-stimulation in different tumor indications 
and among various patients, but also to identify possible additional combination partners, e.g. 
targeting the co-inhibitory signalling axis. 
 
To address this, more repetitions with optimized assays conditions need to be done. 
Considering the minor changes upon ICOS co-stimulation detected by scRNAseq analysis, 
outliers could be the cells responding to ICOS therapy. In addition, more data at different 
time point could help to highlight the multiple levels of ICOS-mediated immune cell 
responses.  
 
One question that remains is the impact of ICOS co-stimulation in TCB-mediated anti-tumor 
response. Does the higher T cell activation translate to an improved and long-lasting 
anti-tumor response? In vitro we were not able to detect enhanced T cell killing, most 
probably because ICOS signalling is rather affecting CD4+- Th cells instead of cytotoxic 
CD8+- T cells. An in vivo efficacy study would be a next step to determine the effect of 
ICOS co-stimulation on T cell memory formation to check our hypothesis that enhanced T 
cell immunity results in an improved and long-lasting anti-tumor response.  
 
Given the reported expression of ICOS on distinct T cell subtypes, such as Th17, Tfh and 
Treg cells, but also on activated T conventional cells, one can easily imagine its complex role 
in T cell co-stimulation (Hutloff et al., 1999, Paulos et al., 2010, Strauss et al., 2008, Weber 
et al., 2015). Many more in-depth analyses of each of the subsets need to be done to unravel 





Overall it could be shown that ICOS, despite its complex biological role, may serve as a 
promising candidate to further boost TCB-mediated T cell activation and thereby improve 






°C   Degree Celsius 
Ab  Antibody 
ADCC  Antibody-dependent cellular cytotoxicity 
ADCP  Antibody-dependent cellular phagocytosis 
APC  Antigen presenting cells  
ATCC American Type Culture Collection 
CD  Cluster of differentiation  
CEA  Carcinoembryonic antigen  
CTLA-4  Cytotoxic T-lymphocyte-associated protein 4 
DC  Dendritic cell 
DMEM  Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid  
E:T Effector to target  
Fab  Fragment, antigen binding 
FACS  Fluorescence-activated cell sorting 
FAP  Fibroblast activation protein-α 
Fc  Fragment crystallizable 
FcR Fc receptor 
FCS Fetal calf serum 
FITC  Fluorescein isothiocyanate 
ICOS  Inducible T cell co-stimulator 
ICOSL  Inducible T cell co-stimulator ligand 
IFN- Interferon alpha 
IFN-γ  Interferon gamma 
IgG  Immunoglobulin G 
IL-2 Interleukin-2 
LDH Lactate dehydrogenase 
MEthOH 2-beta Mercaptoetanol 
MFI  Median fluorescence intensity 




NEAA  Non-essential amino acids 
NFkB Nuclear factor kappa-light-chain-enhancer of activated B cells 
ns Not significant 
PBMC  Peripheral blood mononuclear cell 
PBS Phosphate-buffered saline 
PD-1  Programmed cell death protein 1 
PD-L1  Programmed death-ligand 1 
PE Phycoerythrin  
PFA Paraformaldehyde 
PI3K  Phosphatidylinositol 3-kinase 
RNA Ribonucleic acid 
Rpm  Rotations per min 
RPMI Roswell Park Memorial Institute  
scRNAseq single cell RNA sequencing 
SEC  Size exclusion chromatography 
TCB  T cell bispecific 
TCR  T cell receptor 
Tcyt T cytotoxic cell  
Tfh  T follicular helper cell 
TGF  Transforming growth factor 
Th  T helper cell 
TIL Tumor infiltrating lymphocyte 
TNFR  Tumor necrosis factor receptor 
Treg  T regulatory cell 
U Unit 
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